Healthcare giant Johnson & Johnson (JNJ) will kick off pharma earnings for the fourth-quarter as it posts its quarterly and full year
Categories
Health Care
Why Ligand Pharma, Viking Therapeutics tumbled yesterday, but is gaining today
Shares of Ligand Pharmaceuticals (LGND) took a beating on Wednesday after a bearish report by Citron Research led by short-seller Andrew Left
Microsoft-Walgreens deal highlights an emerging trend in healthcare sector
While the healthcare sector is witnessing a dramatic change in the way companies operate, marked by high-profile partnerships, the tech firms joining
UnitedHealth beats estimates on Q4 results
UnitedHealth Group (UNH) surpassed market expectations on both revenue and earnings for the fourth quarter of 2018. Shares were up 1.5% in
Verona Pharma stock plunges to all time low on disappointing trial
Verona Pharma plc (VRNA) stock plunged to an all-time low of $5.76 on Monday as its lead chronic inflammatory lung disease treating
Aurora gets bigger with Whistler buyout as cannabis boom gains traction
The cannabis market seems to be on the verge of an explosion - with the majority of companies expediting their expansion programs
Earnings preview: Strong Q4 results might lift UnitedHealth Group’s stock
UnitedHealth Group (UNH) is scheduled to report fourth-quarter 2018 earnings results on Tuesday, January 15. Analysts expect the company to report earnings
Axsome Therapeutics almost doubles on positive outcome from Alzheimer’s disease trial
Clinical stage biopharmaceutical company Axsome Therapeutics (AXSM) announces positive outcome for ADVANCE-1 trial associated with the treatment of Alzheimer's disease. Shares of Axsome Therapeutics
In a massive deal, Eli Lilly acquires Loxo Oncology
Eli Lilly and Company (LLY) on Monday announced that it would acquire a small biopharmaceutical startup that develops cancer treatment, Loxo Oncology
Flexion Therapeutics plunges after reporting preliminary Q4 financial results
Flexion Therapeutics (Nasdaq: FLXN) reported its preliminary fourth quarter earnings results after the bell today. The biopharmaceutical company's Q4 revenue is expected to be
Johnson & Johnson dips on revenue decline in India
Johnson & Johnson (JNJ) shares fell 1% on Thursday after the company reported a 3% sales dip in India in the year
Bristol-Myers Squibb swallows Celgene for $74-bln; Celgene stock surges
Bristol-Myers Squibb (NYSE: BMY) acquired its peer Celgene (NASDAQ: CELG) in a $74-billion cash-and-stock deal. Under the agreement terms, Celgene shareholders will
Cambrex Corp. completes acquisition of Avista Pharma solutions
Life sciences company Cambrex Corp. (CBM) Wednesday completed its previously announced acquisition of Avista Pharma Solutions, a biotech firm engaged in the
Aphria rejects Green Growth Brands’ $2.1-bln buyout offer
Aphria Inc. (NYSE: APHA and TSX: APHA) turned down the acquisition proposal by Xanthic Biopharma d.b.a. Green Growth Brands (CSE: GGB) on
Thailand legalizes medical use of cannabis, opens up a new region for pot stocks
After Uruguay and Canada, Thailand has now amended its drug law to legalize marijuana for medical purposes. However, unlike the other two
Budweiser-parent mulls pot-based drinks, inks JV with Tilray
The world’s largest brewery and the parent company of Budweiser, AB InBev (BUD), has given potheads more reasons to cheer ahead of
GSK teams up with Pfizer to announce major changes to business
GlaxoSmithKline plc (GSK) and Pfizer Inc. (PFE) have decided to combine their consumer health businesses in an all-equity transaction that is expected
Merck strengthens animal health division with $2.4-bln Antelliq buyout
Taking a cue from the growing demand for animal care products, healthcare service providers and pharma companies are enhancing their offerings in
Eli Lilly to collaborate with AC Immune for the treatment of Alzheimer’s disease
Eli Lilly (NYSE: LLY) partners with Switzerland-based AC Immune (Nasdaq: ACIU) to research and develop the potential treatment for Alzheimer's disease and
Arrowhead Pharmaceuticals reports a loss of 12 cents per share in Q4
Arrowhead Pharmaceuticals (ARWR) reported Q4 and fiscal 2018 earnings results after the bell today. For the fourth quarter ended September 30, 2018, the
Merck announces management changes
Merck (MRK) announced that Adam Schechter, President of Global Human Health (GHH) division will step down from his present role at the